Semaglutide: The GLP-1 Receptor Agonist
The single-target incretin agonist that anchored the modern GLP-1 research class, mechanism, the major trials, and where the evidence has limits.
A single-target incretin agonist
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a single-target incretin compound, and the baseline of the modern metabolic research class. Tirzepatide adds the GIP receptor to it; retatrutide adds both GIP and glucagon.
The pathway
- GLP-1 receptor: an incretin target linked in research to glucose-dependent insulin signaling, gastric emptying, and satiety pathways. Semaglutide acts on this single receptor with high potency and a long half-life.
Where semaglutide fits
As the single-target anchor of the class, semaglutide is the baseline the multi-agonists build on: tirzepatide adds GIP, retatrutide adds GIP and glucagon. It stays the comparator the newer compounds get measured against.
What the research has examined
Semaglutide has one of the largest clinical evidence bases in the class. A 68-week phase 3 obesity trial (Wilding et al., *NEJM* 2021, STEP 1) studied its effect on body weight, and a large cardiovascular-outcomes trial (Lincoff et al., *NEJM* 2023, SELECT) examined cardiovascular endpoints in people with overweight or obesity without diabetes. These are findings from controlled research trials.
Limitations and open questions
- Investigational supply. Research compound, not an approved product; not for human use.
- Class-typical adverse events. Gastrointestinal effects were the most frequently reported in trials.
- Single-target ceiling. As a GLP-1-only agonist it doesn't engage the GIP or glucagon pathways, the rationale behind the dual and triple agonists now under study.
For laboratory research use only. Not for human consumption.